Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a8e20137e10efebd66f7b326dc42151 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3519ea242d97a904badff9271f63de45 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-61 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
filingDate |
2017-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12a90f0449c6d100e6c134378d7def7b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e5e86397bc8bb0eb8f3813aeb5e3c53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25397fdb645e9c5f53b4a898d695a4a8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbbce06881a78edbd2e4eefe4839953e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df6ad17cb999849a87b4ea0f409bf6fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f53066e2c96d4020d6fb15ec1b3665e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_769665096c279b2a770e6b282d5c923e |
publicationDate |
2019-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2019224281-A1 |
titleOfInvention |
PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN |
abstract |
A method for treating growth hormone deficiency, including administering a human growth hormone fusion protein (GX-H9). A method includes administering a pharmaceutical composition containing an hGH fusion protein (GX-H9) and a pharmaceutically acceptable carrier, wherein the fusion protein (GX-H9) is administered once a week at a dose of 0.4 to 1.6 mg per body weight kg of a pediatric patient, or administered once every two weeks at a dose of 0.8 to 3.2 mg per body weight kg of a pediatric patient. |
priorityDate |
2016-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |